Navigation Links
Nventa Appoints Gordon H. Busenbark to Board of Directors
Date:5/28/2008

- Busenbark Provides Additional Global Corporate Finance, Management and

Manufacturing Experience -

SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today the appointment of Gordon H. Busenbark to the company's board of directors. Mr. Busenbark currently serves as the chief financial officer of Xytis Pharmaceuticals, a privately held development-stage specialty pharmaceuticals company focused on diseases of the central nervous system.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"With his extensive experience in the pharmaceutical, biotech and vaccine industries, Gordon is a valuable addition to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His 28 years of industry experience include overseeing billion dollar businesses in both the U.S. and Europe. We believe this key global experience, coupled with his proven track record in corporate finance and manufacturing, will serve Nventa well as we continue to advance our lead product candidate through development and toward commercialization."

Prior to joining Xytis in 2007, Mr. Busenbark was the chief financial officer of Encysive Pharmaceuticals, a publicly traded specialty pharmaceuticals company focused on vascular disease. In this role, he was responsible for securing external financing, all aspects of Security and Exchange Commission (SEC) reporting, Sarbanes-Oxley compliance, budgeting, forecasting, strategic planning and investor relations activities. From 1981 through 2004, Mr. Busenbark held various leadership positions with Baxter Healthcare Corporation, including president of Baxter BioScience's plasma therapeutics business in Vienna, Austria. Mr. Busenbark began his career as a senior financial analyst at Burroughs Corporation. He received a bachelor of science degree in accounting and an MBA from the University of Utah in Salt Lake City.

"Nventa's HspE7 therapeutic vaccine for the treatment of HPV-related diseases places the company at the center of a very exciting segment of the drug development industry and I am pleased to be connected to the company's important work," said Mr. Busenbark. "I look forward to collaborating with the other members of the Nventa board and leveraging my industry experience to help the company achieve success."

About Nventa Biopharmaceuticals Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN.

For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at http://www.nventacorp.com.


'/>"/>
SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
10. Codexis Appoints Singapore Laboratories Managing Director
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):